Inventiva (IVEVF) Non Operating Interest Expenses (2019 - 2022)
Inventiva (IVEVF) posted Non Operating Interest Expenses of -$180583.8 for Q4 2022, down 420.49% on a QoQ basis from $56345.7 in Q3 2022, and down 292.51% year-over-year from $93805.6 in Q4 2021.
Analysis
Inventiva (IVEVF) Non Operating Interest Expenses (2019 - 2022) Analysis & Trends
Inventiva has reported Non Operating Interest Expenses for 4 years, with the latest figure at -$180583.8 in Q4 2022.
- On a quarterly basis, Non Operating Interest Expenses fell 292.51% year-over-year to -$180583.8 in Q4 2022; TTM through Dec 2022 was -$2.7 million, a 49.0% increase from a year earlier, with the FY2025 full-year figure at -$252.5 million, down 165.75% from the prior year.
- Non Operating Interest Expenses was -$180583.8 for Q4 2022 at Inventiva, down from $56345.7 in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $93805.6 in Q4 2021, with the low at -$2.7 million in Q1 2021.
- Average Non Operating Interest Expenses over 4 years is -$605781.6, with a median of -$30840.9 recorded in 2020.
- The largest YoY upside for Non Operating Interest Expenses was 337.09% in 2021 against a maximum downside of 18794.71% in 2021.
- Over 4 years, Non Operating Interest Expenses stood at -$46489.3 in 2019, then soared by 146.16% to $21461.2 in 2020, then jumped by 337.09% to $93805.6 in 2021, then plunged by 292.51% to -$180583.8 in 2022.
- The last three Non Operating Interest Expenses figures came in at -$180583.8 (Q4 2022), $56345.7 (Q3 2022), and $93805.6 (Q4 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.70 Bn | 621.95 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 440.80 Bn | 434.23 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.37 Bn | 258.68 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 158.89 Bn | 147.19 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 44.38 Bn | 44.38 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.28 Bn | 20.74 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | 2.90 Mn |
| 10 | Inventiva | 693.72 Mn | 693.72 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | -180,583.78 |
| Sep 22, 2022 | 56,345.74 |
| Dec 31, 2021 | 93,805.62 |
| Jun 30, 2021 | -2.64 Mn |
| Mar 31, 2021 | -2.71 Mn |
| Dec 31, 2020 | 21,461.22 |
| Jun 30, 2020 | -30,840.88 |
| Mar 31, 2020 | -14,351.21 |
| Dec 31, 2019 | -46,489.28 |